SeraNovo B.V. has signed a second license agreement with Carna Biosciences, Inc., a company developing kinase inhibitors. Under the agreement, the companies will expand their existing collaboration to jointly develop an oral formulation of a new active ingredient with enhanced bioavailability. Using its Deep Eutectic Solvent (DES) formulation platform, SeraNovo is formulating one of Carna’s drugs to increase its oral bioavailability. The DES formulation platform is based on GRAS excipients that ...